Loading...

Atrion

Nasdaq:ATRI
Snowflake Description

Flawless balance sheet with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ATRI
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
ATRI Share Price and Events
7 Day Returns
-4.3%
NasdaqGS:ATRI
-5.7%
US Medical Equipment
-0.3%
US Market
1 Year Returns
36.8%
NasdaqGS:ATRI
12.2%
US Medical Equipment
7%
US Market
ATRI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Atrion (ATRI) -4.3% 2.6% 13.6% 36.8% 116.1% 204.7%
US Medical Equipment -5.7% -7.1% 1.3% 12.2% 49.5% 91.1%
US Market -0.3% 2.2% 8.5% 7% 37.7% 46.8%
1 Year Return vs Industry and Market
  • ATRI outperformed the Medical Equipment industry which returned 12.2% over the past year.
  • ATRI outperformed the Market in United States of America which returned 7% over the past year.
Price Volatility
ATRI
Industry
5yr Volatility vs Market

Value

 Is Atrion undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Atrion to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Atrion.

NasdaqGS:ATRI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:ATRI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.928 (1 + (1- 21%) (0%))
0.952
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.952 * 5.96%)
8.4%

Discounted Cash Flow Calculation for NasdaqGS:ATRI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Atrion is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:ATRI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.4%)
2019 27.64 Est @ -8.49% 25.50
2020 26.23 Est @ -5.13% 22.32
2021 25.50 Est @ -2.77% 20.02
2022 25.21 Est @ -1.12% 18.26
2023 25.22 Est @ 0.04% 16.85
2024 25.44 Est @ 0.84% 15.68
2025 25.79 Est @ 1.41% 14.66
2026 26.26 Est @ 1.81% 13.77
2027 26.81 Est @ 2.08% 12.97
2028 27.42 Est @ 2.28% 12.24
Present value of next 10 years cash flows $172.27
NasdaqGS:ATRI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $27.42 × (1 + 2.73%) ÷ (8.4% – 2.73%)
$496.61
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $496.61 ÷ (1 + 8.4%)10
$221.64
NasdaqGS:ATRI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $172.27 + $221.64
$393.91
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $393.91 / 1.85
$212.61
NasdaqGS:ATRI Discount to Share Price
Calculation Result
Value per share (USD) From above. $212.61
Current discount Discount to share price of $869.97
= -1 x ($869.97 - $212.61) / $212.61
-309.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Atrion is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Atrion's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Atrion's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ATRI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $18.49
NasdaqGS:ATRI Share Price ** NasdaqGS (2019-04-18) in USD $869.97
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 38.66x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Atrion.

NasdaqGS:ATRI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ATRI Share Price ÷ EPS (both in USD)

= 869.97 ÷ 18.49

47.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atrion is overvalued based on earnings compared to the US Medical Equipment industry average.
  • Atrion is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Atrion's expected growth come at a high price?
Raw Data
NasdaqGS:ATRI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 47.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-1.9%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.29x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Atrion, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Atrion's assets?
Raw Data
NasdaqGS:ATRI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $113.74
NasdaqGS:ATRI Share Price * NasdaqGS (2019-04-18) in USD $869.97
United States of America Medical Equipment Industry PB Ratio Median Figure of 184 Publicly-Listed Medical Equipment Companies 4.14x
United States of America Market PB Ratio Median Figure of 5,182 Publicly-Listed Companies 1.91x
NasdaqGS:ATRI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ATRI Share Price ÷ Book Value per Share (both in USD)

= 869.97 ÷ 113.74

7.65x

* Primary Listing of Atrion.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atrion is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Atrion's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Atrion has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Atrion expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Atrion, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Atrion expected to grow at an attractive rate?
  • Atrion's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Atrion's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • Unable to compare Atrion's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ATRI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ATRI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -1.9%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ATRI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ATRI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NasdaqGS:ATRI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 152 43 34
2018-09-30 152 43 35
2018-06-30 150 48 34
2018-03-31 147 47 35
2017-12-31 147 47 37
2017-09-30 146 46 34
2017-06-30 146 43 33
2017-03-31 146 40 31
2016-12-31 143 37 28
2016-09-30 143 38 28
2016-06-30 142 38 28
2016-03-31 144 40 28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Atrion's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if Atrion is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ATRI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Atrion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ATRI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NasdaqGS:ATRI Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 18.49
2018-09-30 18.97
2018-06-30 18.30
2018-03-31 18.99
2017-12-31 19.82
2017-09-30 18.22
2017-06-30 18.10
2017-03-31 16.74
2016-12-31 15.12
2016-09-30 15.39
2016-06-30 15.46
2016-03-31 15.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Atrion will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Atrion's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Atrion has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Atrion performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Atrion's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Atrion's year on year earnings growth rate has been positive over the past 5 years.
  • Atrion's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Atrion's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.
Earnings and Revenue History
Atrion's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Atrion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ATRI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 152.45 34.26 24.56 5.51
2018-09-30 151.55 35.15 24.63 5.89
2018-06-30 150.17 33.90 24.37 5.83
2018-03-31 147.49 35.13 24.16 5.60
2017-12-31 146.60 36.59 23.68 5.80
2017-09-30 145.87 33.52 23.31 6.05
2017-06-30 145.80 33.16 22.62 6.47
2017-03-31 145.78 30.59 22.01 6.70
2016-12-31 143.49 27.58 21.93 6.57
2016-09-30 142.57 28.06 21.72 6.13
2016-06-30 142.11 28.25 21.88 6.13
2016-03-31 143.62 28.27 22.33 6.20
2015-12-31 145.73 28.93 22.13 6.35
2015-09-30 146.05 28.92 22.03 6.53
2015-06-30 145.30 28.80 22.37 6.19
2015-03-31 142.67 28.21 22.38 5.67
2014-12-31 140.76 27.81 22.42 5.29
2014-09-30 139.92 27.54 22.39 4.60
2014-06-30 137.34 27.52 21.98 4.53
2014-03-31 134.92 27.15 21.16 4.33
2013-12-31 131.99 26.58 20.83 4.29
2013-09-30 128.64 25.71 20.06 4.43
2013-06-30 125.23 25.29 19.34 4.03
2013-03-31 123.32 24.89 19.01 3.92
2012-12-31 119.06 23.63 18.75 3.77
2012-09-30 116.08 24.12 18.53 3.35
2012-06-30 115.91 23.64 18.58 3.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Atrion has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Atrion used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • Atrion's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Atrion's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Atrion has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Atrion's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Atrion's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Atrion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Atrion's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Atrion's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Atrion has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Atrion Company Filings, last reported 3 months ago.

NasdaqGS:ATRI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 210.77 0.00 68.44
2018-09-30 205.16 0.00 65.50
2018-06-30 198.06 0.00 60.24
2018-03-31 190.97 0.00 54.98
2017-12-31 184.39 0.00 65.60
2017-09-30 178.45 0.00 59.95
2017-06-30 172.32 0.00 47.30
2017-03-31 167.70 0.00 46.55
2016-12-31 162.99 0.00 44.10
2016-09-30 159.02 0.00 38.80
2016-06-30 153.59 0.00 30.82
2016-03-31 148.55 0.00 27.99
2015-12-31 144.10 0.00 28.39
2015-09-30 139.21 0.00 23.52
2015-06-30 138.17 0.00 19.62
2015-03-31 139.30 0.00 19.06
2014-12-31 149.57 0.00 23.86
2014-09-30 156.34 0.00 45.10
2014-06-30 149.87 0.00 41.67
2014-03-31 150.63 0.00 42.61
2013-12-31 148.99 0.00 46.91
2013-09-30 149.24 0.00 39.17
2013-06-30 143.65 0.00 32.84
2013-03-31 139.68 0.00 20.43
2012-12-31 134.83 0.00 16.18
2012-09-30 150.51 0.00 38.70
2012-06-30 144.00 0.00 25.77
  • Atrion has no debt.
  • Atrion has not taken on any debt in the past 5 years.
  • Atrion has no debt, it does not need to be covered by operating cash flow.
  • Atrion has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Atrion's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Atrion has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Atrion's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.62%
Current annual income from Atrion dividends.
If you bought $2,000 of Atrion shares you are expected to receive $12 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Atrion's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.39%).
  • Atrion's dividend is below the markets top 25% of dividend payers in United States of America (3.62%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ATRI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ATRI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
NasdaqGS:ATRI Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-02-26 5.400 0.637
2018-11-12 5.400 0.716
2018-08-14 5.400 0.809
2018-08-07 4.800 0.749
2018-02-27 4.800 0.789
2017-11-08 4.800 0.793
2017-08-15 4.800 0.737
2017-05-23 4.200 0.690
2017-02-23 4.200 0.855
2016-11-10 4.200 0.870
2016-11-03 4.200 0.954
2016-05-25 3.600 0.829
2016-02-23 3.600 0.917
2015-11-16 3.600 0.940
2015-08-04 3.600 0.950
2015-05-21 3.000 0.774
2015-03-03 3.000 0.896
2014-11-14 3.000 0.899
2014-09-03 3.000 0.952
2014-05-22 2.560 0.821
2014-03-03 2.560 0.854
2013-11-07 2.560 0.914
2013-08-14 2.560 1.005
2013-05-23 2.240 0.978
2013-02-25 2.240 1.129
2012-11-08 2.240 1.138
2012-08-21 2.240 1.054
2012-05-18 1.960 0.938
2012-02-21 1.960 0.905
2011-11-07 1.960 0.817
2011-08-16 1.960 0.934
2011-05-26 1.680 0.868
2011-03-02 1.680 0.974
2010-11-03 1.680 0.972
2010-08-03 1.680 1.122
2010-05-18 1.440 1.042
2010-01-04 1.440 0.968
2009-11-12 1.440 1.011
2009-08-04 1.440 1.075
2009-05-21 1.200 0.972
2009-04-21 1.200 1.295

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atrion is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • Atrion is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Atrion's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Atrion's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Atrion's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Atrion afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Atrion has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Atrion's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Battat
COMPENSATION $4,315,721
AGE 48
TENURE AS CEO 7.9 years
CEO Bio

Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a subsidiary of ATRION Corp. since January 2006. He served as the Chief Operating Officer at ATRION Corp. since May 15, 2007 until May 2011. He served as Vice President Business Development and General Counsel of Halkey-Roberts from February 2005 to January 2006. From 2002 to 2004, Mr. Battat was engaged in the private practice of law. Mr. Battat holds a Bachelor of Arts degree from Harvard University and a Juris Doctor degree from Columbia University School of Law.

CEO Compensation
  • David's compensation has increased by more than 20% in the past year.
  • David's remuneration is about average for companies of similar size in United States of America.
Management Team

Emile Battat

TITLE
Executive Chairman
COMPENSATION
$3M
AGE
80

David Battat

TITLE
President & CEO
COMPENSATION
$4M
AGE
48
TENURE
7.9 yrs

Jeffery Strickland

TITLE
VP, CFO
COMPENSATION
$795K
AGE
59
TENURE
22.2 yrs
Board of Directors Tenure

Average tenure and age of the Atrion board of directors in years:

17.2
Average Tenure
73
Average Age
  • The average tenure for the Atrion board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Emile Battat

TITLE
Executive Chairman
COMPENSATION
$3M
AGE
80
TENURE
21.3 yrs

Hugh Morgan

TITLE
Independent Director
COMPENSATION
$132K
AGE
89
TENURE
31.3 yrs

Roger Stebbing

TITLE
Lead Independent Director
COMPENSATION
$132K
AGE
77
TENURE
11.3 yrs

John Stupp

TITLE
Independent Director
COMPENSATION
$140K
AGE
68
TENURE
34.3 yrs

Nicky Spaulding

TITLE
Independent Director
COMPENSATION
$126K
AGE
54
TENURE
13.2 yrs

Preston Athey

TITLE
Independent Director
COMPENSATION
$124K
AGE
69
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
29. Nov 18 Sell Jeffery Strickland Individual 27. Nov 18 28. Nov 18 -2,000 $771.00 $-1,536,132
X
Management checks
We assess Atrion's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Atrion has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should We Worry About Atrion Corporation's (NASDAQ:ATRI) P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Atrion has a price to earnings ratio of 47.71, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Atrion Corporation (NASDAQ:ATRI) Earns Among The Best Returns In Its Industry

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Return On Capital Employed (ROCE): What is it? … ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business.

Simply Wall St -

Does Atrion Corporation's (NASDAQ:ATRI) Past Performance Indicate A Weaker Future?

Today I will assess ATRI's latest performance announced on 31 December 2018 and compare these figures to its longer term trend and industry movements. … ATRI's trailing twelve-month earnings (from 31 December 2018) of US$34m has? … Furthermore, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 6.0%, indicating the rate at which ATRI is growing has slowed down

Simply Wall St -

Should You Be Worried About Insider Transactions At Atrion Corporation (NASDAQ:ATRI)?

The Last 12 Months Of Insider Transactions At Atrion. … In the last twelve months, the biggest single sale by an insider was when Vice President Jeffery Strickland sold US$1.5m worth of shares at a price of US$771 per share. … Jeffery Strickland was the only individual insider to sell shares in the last twelve months

Simply Wall St -

Can You Imagine How Chuffed Atrion's Shareholders Feel About Its 181% Share Price Gain?

One great example is Atrion Corporation (NASDAQ:ATRI) which saw its share price drive 181% higher over five years. … While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. … One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price.

Simply Wall St -

What does Atrion Corporation's (NASDAQ:ATRI) Balance Sheet Tell Us About Its Future?

The direct benefit for Atrion Corporation (NASDAQ:ATRI), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is ATRI right in choosing financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Is Atrion Corporation's (NASDAQ:ATRI) CEO Pay Justified?

David Battat has been the CEO of Atrion Corporation (NASDAQ:ATRI) since 2011. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does David Battat's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Could Atrion Corporation's (NASDAQ:ATRI) Investor Composition Influence The Stock Price?

A look at the shareholders of Atrion Corporation (NASDAQ:ATRI) can tell us which group is most powerful. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is Atrion Corporation's (NASDAQ:ATRI) P/E Ratio Really That Good?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … We'll look at Atrion Corporation's (NASDAQ:ATRI) P/E ratio and reflect on what it tells us about the company's share price. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

How Much Are Atrion Corporation (NASDAQ:ATRI) Insiders Taking Off The Table?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … That means that even when the share price was below the current price of US$773, an insider wanted to cash in some shares.

Simply Wall St -

Company Info

Description

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company’s cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Details
Name: Atrion Corporation
ATRI
Exchange: NasdaqGS
Founded: 1944
$1,611,842,137
1,852,756
Website: http://www.atrioncorp.com
Address: Atrion Corporation
One Allentown Parkway,
Allen,
Texas, 75002,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ATRI Common Stock Nasdaq Global Select US USD 02. Jan 1969
Number of employees
Current staff
Staff numbers
570
Atrion employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 23:32
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2018/02/27
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.